CN1268362A - 逆转肝纤维化、肝硬化的中药复方及其制备方法 - Google Patents
逆转肝纤维化、肝硬化的中药复方及其制备方法 Download PDFInfo
- Publication number
- CN1268362A CN1268362A CN 99103265 CN99103265A CN1268362A CN 1268362 A CN1268362 A CN 1268362A CN 99103265 CN99103265 CN 99103265 CN 99103265 A CN99103265 A CN 99103265A CN 1268362 A CN1268362 A CN 1268362A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- radix
- active component
- treatment
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims description 23
- 239000003814 drug Substances 0.000 title description 72
- 150000001875 compounds Chemical class 0.000 title description 36
- 210000004185 liver Anatomy 0.000 title description 15
- 206010016654 Fibrosis Diseases 0.000 title description 12
- 230000004761 fibrosis Effects 0.000 title description 12
- 208000019425 cirrhosis of liver Diseases 0.000 claims abstract description 28
- 208000006454 hepatitis Diseases 0.000 claims abstract description 10
- 239000000284 extract Substances 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims abstract description 6
- 206010008909 Chronic Hepatitis Diseases 0.000 claims abstract description 5
- 238000011282 treatment Methods 0.000 claims description 70
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 50
- 206010019668 Hepatic fibrosis Diseases 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 14
- 239000002994 raw material Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 241000628997 Flos Species 0.000 claims description 13
- 239000000654 additive Substances 0.000 claims description 12
- 239000009636 Huang Qi Substances 0.000 claims description 11
- 239000000341 volatile oil Substances 0.000 claims description 10
- 239000002552 dosage form Substances 0.000 claims description 9
- 101000623895 Bos taurus Mucin-15 Proteins 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 231100000283 hepatitis Toxicity 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 2
- 229940126680 traditional chinese medicines Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 239000000890 drug combination Substances 0.000 claims 4
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 1
- 241000244355 Ligusticum Species 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 235000008216 herbs Nutrition 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 229960004756 ethanol Drugs 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 17
- 239000000835 fiber Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 13
- 229940079593 drug Drugs 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000001575 pathological effect Effects 0.000 description 9
- 230000002441 reversible effect Effects 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 206010028851 Necrosis Diseases 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000017074 necrotic cell death Effects 0.000 description 7
- 239000006187 pill Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 208000002672 hepatitis B Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000005229 liver cell Anatomy 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 3
- 102000012422 Collagen Type I Human genes 0.000 description 3
- 108010022452 Collagen Type I Proteins 0.000 description 3
- 102000002734 Collagen Type VI Human genes 0.000 description 3
- 108010043741 Collagen Type VI Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000000151 deposition Methods 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 210000004177 elastic tissue Anatomy 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 102000012432 Collagen Type V Human genes 0.000 description 2
- 108010022514 Collagen Type V Proteins 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 229940000425 combination drug Drugs 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000012317 liver biopsy Methods 0.000 description 2
- 208000018191 liver inflammation Diseases 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 101710142246 External core antigen Proteins 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- HYGYSIDIKIGPJA-UHFFFAOYSA-N chloroform;ethyl acetate;methanol Chemical compound OC.ClC(Cl)Cl.CCOC(C)=O HYGYSIDIKIGPJA-UHFFFAOYSA-N 0.000 description 1
- -1 decoction Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 230000007866 hepatic necrosis Effects 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
治疗组1 治疗组2 治疗组3 治疗组4 对照组 | |
服用药剂临床症状改善(%) | 冲剂A 冲剂B 冲剂C 冲剂D 乙肝宁78 56 62 61 22 |
治疗组1 治疗组2 治疗组3 对照组 | |
服用药剂临床症状改善(%) | 汤剂a 汤剂b 汤剂c 丸剂d 乙肝宁62.96 50.14 46.29 67.10 34.48 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN99103265A CN1083721C (zh) | 1999-03-29 | 1999-03-29 | 逆转肝纤维化、肝硬化的中药复方及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN99103265A CN1083721C (zh) | 1999-03-29 | 1999-03-29 | 逆转肝纤维化、肝硬化的中药复方及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1268362A true CN1268362A (zh) | 2000-10-04 |
CN1083721C CN1083721C (zh) | 2002-05-01 |
Family
ID=5271185
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN99103265A Expired - Lifetime CN1083721C (zh) | 1999-03-29 | 1999-03-29 | 逆转肝纤维化、肝硬化的中药复方及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1083721C (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1609476A4 (en) * | 2003-03-05 | 2009-07-01 | Original Image Co Ltd | COMPOSITION FOR TREATING HEPATITIS C |
CN103191186A (zh) * | 2012-01-04 | 2013-07-10 | 天士力制药集团股份有限公司 | 丹参制剂在制备抗肝纤维化药物中的应用 |
CN103330881A (zh) * | 2012-02-07 | 2013-10-02 | 张雨 | 治疗慢性肝炎肝纤维化的中药丸剂及制备方法 |
CN111759968A (zh) * | 2020-07-13 | 2020-10-13 | 何欣怡 | 一种用于治疗肝硬化的中药组合物 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100586474C (zh) * | 2006-12-28 | 2010-02-03 | 北京炎黄麒麟生物技术开发有限公司 | 药物组合物、试剂盒及其应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1065750C (zh) * | 1993-01-19 | 2001-05-16 | 太极集团有限公司 | 肝病冲剂 |
CN1071123C (zh) * | 1998-04-10 | 2001-09-19 | 张俊才 | 一种治疗肝炎肝腹水的中成药 |
-
1999
- 1999-03-29 CN CN99103265A patent/CN1083721C/zh not_active Expired - Lifetime
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1609476A4 (en) * | 2003-03-05 | 2009-07-01 | Original Image Co Ltd | COMPOSITION FOR TREATING HEPATITIS C |
CN103191186A (zh) * | 2012-01-04 | 2013-07-10 | 天士力制药集团股份有限公司 | 丹参制剂在制备抗肝纤维化药物中的应用 |
CN103330881A (zh) * | 2012-02-07 | 2013-10-02 | 张雨 | 治疗慢性肝炎肝纤维化的中药丸剂及制备方法 |
CN111759968A (zh) * | 2020-07-13 | 2020-10-13 | 何欣怡 | 一种用于治疗肝硬化的中药组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN1083721C (zh) | 2002-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101837065B (zh) | 抗肝炎、抗肿瘤及提高机体免疫功能的药物及其制备方法 | |
CN1186071C (zh) | 一种治疗慢性心衰的药物组合物及制备方法 | |
CN1530112A (zh) | 一种抗肝纤维化的药物及其制备方法 | |
CN102416139A (zh) | 一种用于治疗乳腺疾病的中药组合物 | |
CN1323699C (zh) | 一种用于治疗痹病的外用膏药及其制备方法 | |
CN1686511A (zh) | 具有疏肝健脾、养血调经丹栀逍遥的药物及其制备方法 | |
CN102362971B (zh) | 一种治疗冠心病中药及其有效化学组分的制备方法和制剂 | |
CN1083721C (zh) | 逆转肝纤维化、肝硬化的中药复方及其制备方法 | |
CN1836706A (zh) | 一种治疗白细胞减少的中药组合物及其制备和质量控制方法 | |
CN109224038B (zh) | 一种治疗瘀血阻络型肝纤维化的含引经药吴茱萸的中药组合物及其制备方法和应用 | |
CN1709288A (zh) | 一种药物组合物及其制备方法和用途 | |
CN1927324A (zh) | 用于治疗妇女***中药制剂的制备方法 | |
CN1887324A (zh) | 一种中药组合物及其制备方法和质量控制方法 | |
CN1256120C (zh) | 一种治疗慢性***的药物及其制备方法 | |
CN101041037A (zh) | 一种治疗糖尿病肾病的药物组合及其制备方法 | |
CN102895387B (zh) | 一种温补肾阳的药物组合物、制剂及其制备方法 | |
CN1308032C (zh) | 一种治疗功能失调性子宫出血的药物组合物及其制备方法 | |
CN1712060A (zh) | 一种治疗妇女经期疾病的中药合剂的制备方法 | |
CN1242767C (zh) | 一种治疗肝纤维化疾病的中药复方制剂及其制备方法 | |
CN1294948C (zh) | 一种益气健脾滋补肝肾的药物及其制备方法 | |
CN1310669C (zh) | 一种治疗慢性肝炎的药物组合物及其制备方法 | |
CN1943717A (zh) | 一种治疗低血压症的中药组合物及其制备方法 | |
CN100340267C (zh) | 一种治疗脂肪肝的中药制剂 | |
CN1189207C (zh) | 一种提高人体免疫力的中药组合物及其制备方法 | |
CN100342879C (zh) | 治疗肝纤维化的制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHANGHAI HEP TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: BEIJING FRIENDSHIP HOSPITAL ATTACHED TO CAPITAL MEDICAL UNIV. Effective date: 20120409 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100050 XUANWU, BEIJING TO: 201203 PUDONG NEW AREA, SHANGHAI |
|
TR01 | Transfer of patent right |
Effective date of registration: 20120409 Address after: 201203 Shanghai Zhangjiang hi tech Park 720 Cailun Road Lane 1, room 231 Patentee after: Shanghai HEP Medical Technology Co.,Ltd. Address before: 100050 No. 95, Yongan Road, Beijing, Xuanwu District Patentee before: Beijing Friendship Hospital Attached to Capital Medical Univ. |
|
CX01 | Expiry of patent term |
Granted publication date: 20020501 |
|
CX01 | Expiry of patent term |